Samsung Biologics Co.,Ltd. Stock: price and insider trades · South Korea
삼성바이오로직스
No insider purchase over the last 90 days. The latest, by 조성환, was filed 20 May 2026.
Who traded when
BuySale+17 other insiders
Since the insiders bought
- -5.3%Entry ₩1,240,792 · Close at T+365 ₩1,174,678
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Samsung Biologics Co.,Ltd. Buy (bullish), based on 27 analysts. Average price target: ₩1,879,148.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 50 sharesShareKRXDART:20260806000473
- Other0DART
- 50 sharesShareKRXDART:20260520000330Canonical exit: 18 Aug 2026 (T+90)
25 of 143 declarations
About Samsung Biologics Co.,Ltd.
Sales edge out purchases in the 삼성바이오로직스 (Samsung Biologics Co.,Ltd.) record: 25 against 19, or 43% purchases among open-market trades. No sale carries an amount, and just one purchase does: EUR 22,310, attributed to 진용환 on January 6, 2023.
A South Korean company in the Health Care sector, listed on Korea Exchange and valued at KRW 64.9 trillion, Samsung Biologics has 120 filings from 28 filers, published between February 26, 2021 and August 6, 2026. Insiders hold 74.4% of the capital. The most frequent filer is 이재선 (상무), with 65 filings, one purchase and one sale among them. 삼성물산, filed with the function 대량보유자, signs 4 filings, all sales; 김동중 (부사장) signs 3, also all sales.
Read moreShow less
Annual volume peaks at 49 filings in 2022, against 11 in 2021 and in 2024, 28 in 2025 and 8 in 2026. Between December 9 and December 27, 2024, 4 filers bought. The last twelve months hold 31 filings, of which 4 purchases and 21 sales. Publication comes a median of 6 days after the trade, on 15 filings only.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
